The fibroblast: Sentinel cell and local immune modulator in tumor tissue

International Journal of Cancer

Volumn 108, Issue 2, 2004, Pages 173-180

  Silzle, Tobias ^a   Randolph, Gwendalyn J ^b   Kreutz, Marina ^a   Kunz Schughart, Leoni A ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chemokines; Cytokines; ECM; ECM modulation; Immune cell; Peptide growth factors; Tumor associated fibroblasts

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; KERATINOCYTE GROWTH FACTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; SOMATOMEDIN B; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL MODEL; CELL DIFFERENTIATION; EPITHELIUM TUMOR; EXTRACELLULAR MATRIX; FIBROBLAST; IMMUNOMODULATION; INFLAMMATORY INFILTRATE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; CYTOKINES; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; NEOPLASMS;

EID: 0348012943     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11542     Document Type: Short Survey

References (160)

1. Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997;151:317-22.
2. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001;22:199-204.
3. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science 1998;280:1036-7.
4. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000;6:324-9.
5. Wernert N. The multiple roles of tumour stroma. Virchows Arch 1997;430:433-43.
6. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 2001;264:169-84.
7. Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 2001;11:54-9.
8. Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part I): active stromal participants in tumor development and progression? Histol Histopathol 2002;17:599-621.
9. Kunz-Schughart LA, Knuechel R. Tumor-associated-fibroblasts (part II): functional impact on tumor tissue. Histol Histopathol 2002;17:623-37.
10. Opdenakker G, Van Damme J. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine 1992;4:251-8.
11. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
12. Silzle T, Kreutz M, Dobler MA, Brockhoff G, Knuechel R, Kunz-Schughart LA. Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. Eur J Immunol 2003;33:1311-20.
13. Pakianathan DR. Extracellular matrix proteins and leukocyte function. J Leukoc Biol 1995;57:699-702.
14. Vaday GG, Hershkoviz R, Rahat MA, Lahat N, Cahalon L, Lider O. Fibronectin-bound TNF-alpha stimulates monocyte matrix metalloproteinase-9 expression and regulates chemotaxis. J Leukoc Biol 2000;68:737-47.
15. Vaday GG, Franitza S, Schor H, Hecht I, Brill A, Cahalon L, Hershkoviz R, Lider O. Combinatorial signals by inflammatory cytokines and chemokines mediate leukocyte interactions with extracellular matrix. J Leukoc Biol 2001;69:885-92.
16. Schor H, Vaday GG, Lider O. Modulation of leukocyte behavior by an inflamed extracellular matrix. Dev Immunol 2000;7:227-38.
17. Mackie EJ. Molecules in focus: tenascin-C. Int J Biochem Cell Biol 1997;29:1133-7.
18. Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 2000;19:581-96.
19. Talts JF, Wirl G, Dictor M, Muller WJ, Fassler R. Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. J Cell Sci 1999;112 (Pt 12):1855-64.
20. Loike JD, Cao L, Budhu S, Hoffman S, Silverstein SC. Blockade of alpha 5 beta 1 integrins reverses the inhibitory effect of tenascin on chemotaxis of human monocytes and polymorphonuclear leukocytes through three-dimensional gels of extracellular matrix proteins. J Immunol 2001;166:7534-42.
21. Lightner VA, Slemp CA, Erickson HP. Localization and quantitation of hexabrachion (tenascin) in skin, embryonic brain, tumors, and plasma. Ann NY Acad Sci 1990;580:260-75.
22. Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 2001;61:8586-94.
23. Chiquet-Ehrismann R. Tenascins, a growing family of extracellular matrix proteins. Experientia 1995;51:853-62.
24. Chiquet-Ehrismann R. Anti-adhesive molecules of the extracellular matrix. Curr Opin Cell Biol 1991;3:800-4.
25. Hauzenberger D, Olivier P, Gundersen D, Ruegg C. Tenascin-C inhibits beta1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnlII 1-5 repeats to fibronectin. Eur J Immunol 1999;29:1435-47.
26. Ruegg CR, Chiquet-Ehrismann R, Alkan SS. Tenascin, an extracellular matrix protein, exerts immunomodulatory activities. Proc Natl Acad Sci USA 1989;86:7437-41.
27. Hemesath TJ, Marton LS, Stefansson K. Inhibition of T cell activation by the extracellular matrix protein tenascin. J Immunol 1994;152:5199-207.
28. Hibino S, Kato K, Kudoh S, Yagita H, Okumura K. Tenascin suppresses CD3-mediated T cell activation. Biochem Biophys Res Commun 1998;250:119-24.
29. Gundersen D, Tran-Thang C, Sordat B, Mourali F, Ruegg C. Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering. J Immunol 1997;158:1051-60.
30. de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG. Thrombospondins and tumor angiogenesis. Trends Mol Med 2001;7:401-7.
31. Bertin N, Clezardin P, Kubiak R, Frappart L. Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res 1997;57:396-9.
32. Tobita K, Kijima H, Dowaki S, Oida Y, Kashiwagi H, Ishii M, Sugio Y, Sekka T, Ohtani Y, Tanaka M, Inokuchi S, Makuuchi H. Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int J Oncol 2002;21:1189-95.
33. Ohtani H. Pathophysiologic significance of host reactions in human cancer tissue: desmoplasia and tumor immunity. Tohoku J Exp Med 1999;187:193-202.
34. Oshiba G, Kijima H, Himeno S, Kenmochi T, Kise Y, Tanaka H, Nishi T, Chino O, Shimada H, Machimura T, Tsuchida T, Nakamura M, et al. Stromal thrombospondin-1 expression is correlated with progression of esophageal squamous cell carcinomas. Anticancer Res 1999;19:4375-8.
35. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, Bongarzone I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155:1967-76.
36. Grossfeld GD, Carroll PR, Lindeman N, Meng M, Groshen S, Feng AC, Hawes D, Cote RJ. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression. Urology 2002;59:97-102.
37. Miyanaga K, Kato Y, Nakamura T, Matsumura M, Amaya H, Horiuchi T, Chiba Y, Tanaka K. Expression and role of thrombospondin-1 in colorectal cancer. Anticancer Res 2002;22:3941-8.
38. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000;11:59-69.
39. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 1996;10:1183-91.
40. Sargiannidou I, Zhou J, Tuszynski GP. The role of thrombospondin-1 in tumor progression. Exp Biol Med (Maywood) 2001;226:726-33.
41. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol 2000;19:597-614.
42. Beck C, Schreiber H, Rowley D. Role of TGF-beta in immune-evasion of cancer. Microsc Res Tech 2001;52:387-95.
43. Mansfield PJ, Suchard SJ. Thrombospondin promotes chemotaxis and haptotaxis of human peripheral blood monocytes. J Immunol 1994;153:4219-9.
44. Armant M, Avice MN, Hermann P, Rubio M, Kiniwa M, Delespesse G, Sarfati M. CD47 ligation selectively downregulates human interleukin 12 production. J Exp Med 1999;190:1175-82.
45. Demeure CE, Tanaka H, Mateo V, Rubio M, Delespesse G, Sarfati M. CD47 engagement inhibits cytokine production and maturation of human dendritic cells. J Immunol 2000;164:2193-9.
46. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998;64:275-90.
47. Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, Van Damme J, Mantovani A. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 2000;164:762-7.
48. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
49. Sica A, Saccani A, Mantovani A. Tumor-associated macrophages: a molecular perspective. Int Immunopharmacol 2002;2:1045-54.
50. Reinhold MI, Lindberg FP, Kersh GJ, Allen PM, Brown EJ. Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway. J Exp Med 1997;185:1-11.
51. Ticchioni M, Deckert M, Mary F, Bernard G, Brown EJ, Bernard A. Integrin-associated protein (CD47) is a comitogenic molecule on CD3-activated human T cells. J Immunol 1997;158:677-84.
52. Avice MN, Rubio M, Sergerie M, Delespesse G, Sarfati M. CD47 ligation selectively inhibits the development of human naive T cells into Th1 effectors. J Immunol 2000;165:4624-31.
53. Vallejo AN, Mugge LO, Klimiuk PA, Weyand CM, Goronzy JJ. Central role of thrombospondin-1 in the activation and clonal expansion of inflammatory T cells. J Immunol 2000;164:2947-54.
54. Avice MN, Rubio M, Sergerie M, Delespesse G, Sarfati M. Role of CD47 in the induction of human naive T cell anergy. J Immunol 2001;167:2459-68.
55. Beppu R, Nakamura K, Miyajima-Uchida H, Kuroki M, Khare PD, Yamauchi Y, Yamashita Y, Shirakusa T. Soluble thrombospondin-1 suppresses T cell proliferation and enhances IL-10 secretion by antigen presenting cells stimulated with phytohemagglutinin. Immunol Invest 2001;30:143-56.
56. Li Z, He L, Wilson K, Roberts D. Thrombospondin-1 inbibits TCR-mediated T lymphocyte early activation. J Immunol 2001;166:2427-36.
57. Ticchioni M, Raimondi V, Lamy L, Wijdenes J, Lindberg FP, Brown EJ, Bernard A. Integrin-associated protein (CD47/IAP) contributes to T cell arrest on inflammatory vascular endothelium under flow. FASEB J 2001;15:341-50.
58. Li Z, Calzada MJ, Sipes JM, Cashel JA, Krutzsch HC, Annis DS, Mosher DF, Roberts DD. Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol 2002;157:509-19.
59. Barilla ML, Carsons SE. Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum 2000;29:252-65.
60. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, Proost P, Van Damme J. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc 2001;69:851-9.
61. Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001;22:571-9.
62. Apte RN, Voronov E. Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 2002;12:277-90.
63. Ito A, Mukaiyama A, Itoh Y, Nagase H, Thogersen IB, Enghild JJ, Sasaguri Y, Mori Y. Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem 1996;271:14657-60.
64. Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998;161:3340-6.
65. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000;289:1202-6.
66. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 2002;100:1160-7.
67. Brocks B, Garin-Chesa P, Behrle E, Park JE, Rettig WJ, Pfizenmaier K, Moosmayer D. Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse. Mol Med 2001;7:461-9.
68. Sedo A, Malik R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta 2001;1550:107-16.
69. Ajami K, Abbott CA, Obradovic M, Gysbers V, Kahne T, McCaughan GW, Gorrell MD. Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family. Biochemistry 2003;42:694-701.
70. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999;277:C1-C9.
71. Öklü R, Hesketh R. The latent transforming growth factor beta binding protein (LTBP) family. Biochem J 2000;352 (Pt 3):601-10.
72. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-76.
73. Kao WJ, Lee D, Schense JC, Hubbell JA. Fibronectin modulates macrophage adhesion and FBGC formation: the role of RGD, PHSRN, and PRRARV domains. J Biomed Mater Res 2001;55:79-88.
74. Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME. Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 1991;51:4978-85.
75. Rosen N, Yee D, Lippman ME, Paik S, Cullen KJ. Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat 1991;18 (Suppl 1):S55-S62.
76. Yee D, Rosen N, Favoni RE, Cullen KJ. The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer. Cancer Treat Res 1991;53:93-106.
77. Giani C, Cullen KJ, Campani D, Rasmussen A. IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: an in situ hybridization and immunohistochemistry study. Breast Cancer Res Treat 1996;41:43-50.
78. Pilichowska M, Kimura N, Fujiwara H, Nagura H. Immunohistochemical study of TGF-alpha, TGF-beta1, EGFR, and IGF-1 expression in human breast carcinoma. Mod Pathol 1997;10:969-75.
79. Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998;35:165-77.
80. Vella V, Sciacca L, Pandini G, Mineo R, Squatrito S, Vigneri R, Belfiore A. The IGF system in thyroid cancer: new concepts. Mol Pathol JID - 9706282 2001;54:121-4.
81. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 2001;61:7318-24.
82. Uchida D, Kawamata H, Omotehara F, Nakashiro K, Kimura-Yanagawa T, Hino S, Begum, NM, Hoque MO, Yoshida H, Sato M, Fujimori T. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 2001;93:489-96.
83. Qian LW, Mizumoto K, Maehara N, Ohuchida K, Inadome N, Saimura M, Nagai E, Matsumoto K, Nakamura T, Tanaka M. Cocultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. Cancer Lett 2003;190:105-12.
84. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 2002;63:317-32.
85. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41-59.
86. Scarpino S, Stoppacciaro A, Ballerini F, Marchesi M, Prat M, Stella MC, Sozzani S, Allavena P, Mantovani A, Ruco LP. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol 2000;156:831-7.
87. Beilmann M, Odenthal M, Jung W, Vande WG, Dienes HP, Schirmacher P. Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood 1997;90:4450-8.
88. Galimi F, Cottone E, Vigna E, Arena N, Boccaccio C, Giordano S, Naldini L, Comoglio PM. Hepatocyte growth factor is a regulator of monocyte-macrophage function. J Immunol 2001;166:1241-7.
89. Beilmann M, Vande WG, Dienes HP, Schirmacher P. Hepatocyte growth factor-stimulated invasiveness of monocytes. Blood 2000;95:3964-9.
90. Adams DH, Harvath L, Bottaro DP, Interrante R, Catalano G, Tanaka Y, Strain A, Hubscher SG, Shaw S. Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. Proc Natl Acad Sci USA 1994;91:7144-8.
91. Francavilla A, Vujanovic NL, Polimeno L, Azzarone A, Iacobellis A, Deleo A, Hagiya M, Whiteside TL, Starzl TE. The in vivo effect of hepatotrophic factors augmenter of liver regeneration, hepatocyte growth factor, and insulin-like growth factor-II on liver natural killer cell functions. Hepatology 1997;25:411-5.
92. van der Voort R, Taher TE, Derksen PW, Spaargaren M, van der Neut R, Pals ST. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res 2000;79:39-90.
93. Skibinski G, Skibinska A, James K. The role of hepatocyte growth factor and its receptor c-met in interactions between lymphocytes and stromal cells in secondary human lymphoid organs. Immunology 2001;102:506-14.
94. Clark R. The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocr Rev 1997;18:157-9.
95. Van Buul-Offers SC, Kooijman R. The role of growth hormone and insulin-like growth factors in the immune system. Cell Mol Life Sci 1998;54:1083-94.
96. Kooijman RK, Scholtens LE, Rijkers GT, Zegers BJ. Differential expression of type I insulin-like growth factor receptors in different stages of human T cells. Eur J Immunol 1995;25:931-5.
97. Welniak LA, Sun R, Murphy WJ. The role of growth hormone in T-cell development and reconstitution. J Leukoc Biol 2002;71:381-7.
98. Balteskard L, Unneberg K, Halvorsen D, Hansen JB, Revhaug A. Effects of insulin-like growth factor 1 on neutrophil and monocyte functions in normal and septic states. JPEN J Parenter Enteral Nutr 1998;22:127-35.
99. Renier G, Clement I, Desfaits AC, Lambert A. Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-alpha production. Endocrinology 1996;137:4611-8.
100. Kooijman R, Willems M, Rijkers GT, Brinkman A, Van Buul-Offers SC, Heijnen CJ, Zegers BJ. Effects of insulin-like growth factors and growth hormone on the in vitro proliferation of T lymphocytes. J Neuroimmunol 1992;38:95-104.
101. Kooijman R, Rijkers GT, Zegers BJ. IGF-I potentiates interleukin-2 production in human peripheral T cells. J Endocrinol 1996;149:351-6.
102. Tu W, Cheung PT, Lau YL. Insulin-like growth factor 1 promotes cord blood T cell maturation and inhibits its spontaneous and phytohemagglutinin-induced apoptosis through different mechanisms. J Immunol 2000;165:1331-6.
103. Walsh PT, O'Connor R. The insulin-like growth factor-I receptor is regulated by CD28 and protects activated T cells from apoptosis. Eur J Immunol 2000;30:1010-8.
104. Walsh PT, Smith LM, O'Connor R. Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes. Immunology 2002;107:461-71.
105. Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 1999;21:339-59.
106. Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 2001;167:2972-8.
107. Smola H, Thiekotter G, Fusenig NE. Mutual induction of growth factor gene expression by epidermal-dermal cell interaction. J Cell Biol 1993;122:417-29.
108. Maas-Szabowski N, Fusenig NE. Interleukin-1-induced growth factor expression in postmitotic and resting fibroblasts. J Invest Dermatol 1996;107:849-55.
109. Rockman SP, Demmler K, Roczo N, Cosgriff A, Phillips WA, Thomas RJ, Whitehead RH. Expression of interleukin-6, leukemia inhibitory factor and their receptors by colonic epithelium and pericryptal fibroblasts. J Gastroenterol Hepatol 2001;16:991-1000.
110. Murakami S, Okada H. Lymphocyte-fibroblast interactions. Crit Rev Oral Biol Med 1997;8:40-50.
111. Jahkola T, Toivonen T, von Smitten K, Blomqvist C, Virtanen I. Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer 1996;69:445-7.
112. Ruiter D, Bogenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 2002;3:35-43.
113. Brouty-Boyé D, Pottin-Clemenceau C, Doucet C, Jasmin C, Azzarone B. Chemokines and CD40 expression in human fibroblasts. Eur J Immunol 2000;30:914-9.
114. Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N. Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 1998;194:335-40.
115. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001;92:1085-91.
116. Mazzucchelli L, Loetscher P, Kappeler A, Uguccioni M, Baggiolini M, Laissue JA, Mueller C. Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Am J Pathol 1996;149:501-9.
117. Negus RP, Stamp GW, Relf MG, Burke F, Malik ST, Bernasconi S, Allavena P, Sozzani S, Mantovani A, Balkwill FR. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995;95:2391-6.
118. Kleine-Lowinski K, Gillitzer R, Kühne-Heid R, Rosl F. Monocytechemo-attractant-protein-1 (MCP-1)-gene expression in cervical intra-epithelial neoplasias and cervical carcinomas. Int J Cancer 1999;82:6-11.
119. Wong MP, Cheung KN, Yuen ST, Fu KH, Chan AS, Leung SY, Chung LP. Monocyte chemoattractant protein-1 (MCP-1) expression in primary lymphoepithelioma-like carcinomas (LELCs) of the lung. J Pathol 1998;186:372-7.
120. Zickus C, Kunkel SL, Simpson K, Evanoff H, Glass M, Strieter RM, Lukacs NW. Differential regulation of C-C chemokines during fibroblast-monocyte interactions: adhesion vs. inflammatory cytokine pathways. Mediators Inflamm 1998;7:269-74.
121. Jiang Y, Zhu JF, Luscinskas FW, Graves DT. MCP-1-stimulated monocyte attachment to laminin is mediated by beta 2-integrins. Am J Physiol 1994;267:C1112-8.
122. Penberthy TW, Jiang Y, Luscinskas FW, Graves DT. MCP-1-stimulated monocytes preferentially utilize beta 2-integrins to migrate on laminin and fibronectin. Am J Physiol 1995;269:C60-8.
123. Carr MW, Alon R, Springer TA. The C-C chemokine MCP-1 differentially modulates the avidity of beta 1 and beta2 integrins on T lymphocytes. Immunity 1996;4:179-87.
124. Weber C, Alon R, Moser B, Springer TA. Sequential regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis. J Cell Biol 1996;134:1063-73.
125. Ashida N, Arai H, Yamasaki M, Kita T. Distinct signaling pathways for MCP-1-dependent integrin activation and chemotaxis. J Biol Chem 2001;276:16555-60.
126. Cambien B, Pomeranz M, Millet MA, Rossi B, Schmid-Alliana A. Signal transduction involved in MCP-1-mediated monocytic transendothelial migration. Blood 2001;97:359-66.
127. Müller R, Zheng M, Mrowietz U. Significant reduction of human monocyte chemotactic response to monocyte-chemotactic protein 1 in patients with primary and metastatic malignant melanoma. Exp Dermatol 1997;6:81-6.
128. Sica A, Saccani A, Bottazzi B, Bernasconi S, Allavena P, Gaetano B, Fei F, LaRosa G, Scotton C, Balkwill F, Mantovani A. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J Immunol 2000;164:733-8.
129. Goede V, Brogelli L, Ziche M, Augustin HG. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 1999;82:765-70.
130. Hogaboam CM, Steinhauser ML, Chensue SW, Kunkel SL. Novel roles for chemokines and fibroblasts in interstitial fibrosis. Kidney Int 1998;54:2152-9.
131. Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Strieter RM, Kunkel SL. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: crosstalk between MCP-1 and leukotriene B4. J Immunol 1999;163:6148-54.
132. Peng L, Shu S, Krauss JC. Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells. Cancer Res 1997;57:4849-54.
133. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000;404:407-11.
134. Sporri B, Müller KM, Wiesmann U, Bickel M. Soluble IL-6 receptor induces calcium flux and selectively modulates chemokine expression in human dermal fibroblasts. Int Immunol 1999;11:1053-8.
135. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della CG, Tura S, Baccarani M, Lemoli RM. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002;100:230-7.
136. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, Blay JY. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998;92:4778-91.
137. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000;1:510-4.
138. Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 2002;39:531-6.
139. Tamm M, Bihl M, Eickelberg O, Stulz P, Perruchoud AP, Roth M. Hypoxia-induced interleukin-6 and interleukin-8 production is mediated by platelet-activating factor and platelet-derived growth factor in primary human lung cells. Am J Respir Cell Mol Biol 1998;19:653-61.
140. Galindo M, Santiago B, Alcami J, Rivero M, Martin-Serrano J, Pablos JL. Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. Clin Exp Immunol 2001;123:36-41.
141. Saed GM, Zhang W, Diamond MP. Molecular characterization of fibroblasts isolated from human peritoneum and adhesions. Fertil Steril 2001;75:763-8.
142. Höckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001;28:36-41.
143. Pilch H, Schlenger K, Steiner E, Brockerhoff P, Knapstein P, Vaupel P. Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts. Int J Gynecol Cancer 2001;11:137-42.
144. Gonzalez-Cuadrado S, Bustos C, Ruiz-Ortega M, Ortiz A, Guijarro C, Plaza JJ, Egido J. Expression of leucocyte chemoattractants by interstitial renal fibroblasts: up-regulation by drugs associated with interstitial fibrosis. Clin Exp Immunol 1996;106:518-22.
145. Struyf S, Van Collie E, Paemen L, Put W, Lenaerts JP, Proost P, Opdenakker G, Van Damme J. Synergistic induction of MCP-1 and -2 by IL-1beta and interferons in fibroblasts and epithelial cells. J Leukoc Biol 1998;63:364-72.
146. Andoh A, Takaya H, Saotome T, Shimada M, Hata K, Araki Y, Nakamura F, Shintani Y, Fujiyama Y, Bamba T. Cytokine regulation of chemokine (IL-8, MCP-1, and RANTES) gene expression in human pancreatic periacinar myofibroblasts. Gastroenterology 2000;119:211-9.
147. Okuno T, Andoh A, Bamba S, Araki Y, Fujiyama Y, Fujiyama M, Bamba T. Interleukin-1beta and tumor necrosis factor-alpha induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts. Scand J Gastroenterol 2002;37:317-24.
148. Rolfe MW, Kunkel SL, Standiford TJ, Orringer MB, Phan SH, Evanoff HL, Burdick MD, Strieter RM. Expression and regulation of human pulmonary fibroblast-derived monocyte chemotactic peptide-1. Am J Physiol 1992;263:L536-45.
149. Barnes PJ. Nuclear factor-kappa B. Int J Biochem Cell Biol 1997;29:867-70.
150. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
151. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-47.
152. Gilmore T, Gapuzan ME, Kalaitzidis D, Starczynowski D. Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer. Cancer Lett 2002;181:1-9.
153. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
154. Anderson IC, Mari SE, Broderick RJ, Mari BP, Shipp MA. The angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast cocultures. Cancer Res 2000;60:269-72.
155. Georganas C, Liu H, Perlman H, Hoffmann A, Thimmapaya B, Pope RM. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol 2000;165:7199-206.
156. Bhat-Nakshatri P, Newton TR, Goulet RJ, Nakshatri H. NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1alpha. Proc Natl Acad Sci USA 1998;95:6971-6.
157. Nozaki S, Sledge GWJ, Nakshatri H. Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochem Biophys Res Commun 2000;275:60-2.
158. Bond M, Baker AH, Newby AC. Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999;264:561-7.
159. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998;435:29-34.
160. Mifflin RC, Saada JI, Di Mari JF, Adegboyega PA, Valentich JD, Powell DW. Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. Am J Physiol Cell Physiol 2002;282:C824-34.